Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.

FIB-4 analyses of incretin therapies versus placebo (three studies; n = 190) did not reach statistical significance (SMD [Hedges’ g] = −2.17; 95 % CI, −5.62 to 1.28; p = 0.217) (Supplemental Figure S2E) . 3.2 Weight loss Five trials (n = 228) comparing incretin therapies with placebo showed a non-significant reduction in percent weight change (SMD [Hedges’ g] = −0.49; 95 % CI, −1.09 to 0.10; p = 0.103), with substantial heterogeneity (I2 = 78.4 %) (Supplemental Figure S3A) .

also in 111,027 other papers